PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer

Most patients (pts) with locally advanced, unresectable non–small cell lung cancer (NSCLC) progress despite concurrent chemoradiation therapy (cCRT). Here we report interim results from a global, phase 3 study (NCT02125461) of the anti-PD-L1 Durvalumab as consolidation therapy in Stage III pts without progression following platinum-based cCRT.

http://ift.tt/2zCNNuT